Suraksha Diagnostic reports 25% total income growth in FY26; EBITDA rises 26% in Q4

Arunika Jain — Thu, 21 May 2026 15:56:42 +0000

Suraksha Diagnostic Limited, the largest integrated diagnostic chain in East India, announced audited financial results for the quarter and financial year ended 31 March 2026, reporting robust growth across key metrics.

For the full financial year FY26, total income reached ₹3,136 million, growing 23% year-on-year from ₹2,559.39 million in FY25. EBITDA expanded by 16% to ₹986 million compared to ₹850.88 million in the prior year. Profit After Tax (PAT) stood at ₹314 million, marking a marginal 1% increase from ₹309.78 million in FY25, with earnings per share (EPS) of ₹6.2 compared to ₹0.21 previously.

In the fourth quarter specifically, total income grew 24.7% to ₹821.97 million from ₹659.12 million in Q4 FY25. EBITDA increased 25.7% to ₹251.55 million against ₹200.05 million year-on-year. However, Q4 PAT declined 14.1% to ₹61.59 million from ₹71.71 million, reflecting a compression in margins from 11% to 7.6%.

Operationally, the company demonstrated strong momentum. Total tests conducted during FY26 reached 8.16 million, a 22% increase from 6.68 million in FY25. Patient volumes grew 14.9% to 1.37 million from 1.19 million. Tests per patient improved to 5.95 from 5.60, whilst average revenue per test increased 0.9% to ₹381. Average revenue per patient rose 7.1% to ₹2,264.

During FY26, Suraksha Diagnostic significantly expanded its operational footprint by adding 2 hubs, 11 spoke centres and 4 Public-Private Partnership (PPP) facilities. The company also launched a genomic laboratory, which has shown strong uptake. Mrs. Ritu Mittal, Joint Managing Director and Chief Executive Officer, commented that centres operational for over two years maintain stable EBITDA margins of 36-37%, demonstrating resilience of the business model. The company continues pursuing an investment strategy focused on scale expansion with expected near-term margin compression to support long-term value creation.

The company operates across West Bengal, Bihar and Assam with accreditations from the College of American Pathologists, the National Accreditation Board for Testing and Calibration Laboratories (NABL), and the National Accreditation Board for Hospitals & Healthcare Providers (NABH).

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Mamta Jain | Business Upturn

Suraksha Diagnostic reports 25% total income growth in FY26; EBITDA rises 26% in Q4